Brief: Imricor Medical Systems Says Visabl-Afl Trial For US FDA Approval Receives Ethics Approval
11/03/2024 01:31
March 11 (Reuters) - Imricor Medical Systems IMR.AX :
* VISABL-AFL TRIAL FOR US FDA APPROVAL RECEIVES ETHICS
APPROVAL AT
CARDIOVASCULAR INSTITUTE OF SOUTH PARIS
Further company coverage: IMR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion